stoxline Quote Chart Rank Option Currency Glossary
  
SI-BONE, Inc. (SIBN)
15.42  0.12 (0.78%)    04-19 16:00
Open: 15.23
High: 15.7
Volume: 576,111
  
Pre. Close: 15.3
Low: 15.1401
Market Cap: 633(M)
Technical analysis
2024-04-19 5:12:16 PM
Short term     
Mid term     
Targets 6-month :  18.77 1-year :  19.66
Resists First :  16.07 Second :  16.84
Pivot price 15.52
Supports First :  14.84 Second :  12.34
MAs MA(5) :  15.31 MA(20) :  15.53
MA(100) :  18.51 MA(250) :  20.93
MACD MACD :  -0.5 Signal :  -0.6
%K %D K(14,3) :  26.7 D(3) :  23.7
RSI RSI(14): 42.8
52-week High :  29.51 Low :  14.84
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ SIBN ] has closed above bottom band by 42.5%. Bollinger Bands are 54% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 15.72 - 15.78 15.78 - 15.82
Low: 14.98 - 15.06 15.06 - 15.12
Close: 15.31 - 15.42 15.42 - 15.51
Company Description

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.

Headline News

Mon, 01 Apr 2024
SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark - Simply Wall St

Thu, 29 Feb 2024
Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report - Simply Wall St

Tue, 27 Feb 2024
Healthcare Stocks Making Moves Tuesday: JANX, VKTX, BIOR, CTMX, NERV, PRGO, CMAX, SIBN - InvestorsObserver

Tue, 27 Feb 2024
Cantor Fitzgerald maintains $25 target on SI-BONE shares - Investing.com

Mon, 26 Feb 2024
Si-Bone: Q4 Earnings Snapshot - Quartz

Mon, 26 Feb 2024
SI-BONE, Inc. (SIBN) Q4 2023 Earnings Call Transcript - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Devices
Shares Out 41 (M)
Shares Float 38 (M)
Held by Insiders 2.3 (%)
Held by Institutions 98.4 (%)
Shares Short 2,440 (K)
Shares Short P.Month 2,320 (K)
Stock Financials
EPS -1.13
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.15
Profit Margin -31.3 %
Operating Margin -32.2 %
Return on Assets (ttm) -15.2 %
Return on Equity (ttm) -32.4 %
Qtrly Rev. Growth 21.6 %
Gross Profit (p.s.) 0
Sales Per Share 3.38
EBITDA (p.s.) -1.02
Qtrly Earnings Growth 0 %
Operating Cash Flow -19 (M)
Levered Free Cash Flow -12 (M)
Stock Valuations
PE Ratio -13.65
PEG Ratio -1.8
Price to Book value 3.7
Price to Sales 4.55
Price to Cash Flow -33.84
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android